Brief: Poland And U.K. Regulatory Authorities Approve Use Of New, Higher-Yielding Manufacturing Process For Nomacopan In Pivotal Clinical Study

Akari Therapeutics

29/03/2023 13:43

March 29 (Reuters) - Akari Therapeutics PLC  AKTX.O :
    * POLAND AND U.K. REGULATORY AUTHORITIES – URPL AND MHRA –
APPROVE
USE OF NEW, HIGHER-YIELDING MANUFACTURING PROCESS FOR NOMACOPAN
IN PIVOTAL CLINICAL STUDY
    * AKARI THERAPEUTICS PLC - PHASE 3 STUDY OF NOMACOPAN IN
PEDIATRIC
HSCT-TMA INCLUDES CLINICAL TRIAL SITES IN POLAND, U.K. AND U.S

Source text for Eikon:  ID:nGNX6xfDyy 
Further company coverage:  AKTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))